Cellipont Bioservices is a cell therapy CDMO with experience in the development and manufacturing of cell therapies. Our leaders have played an instrumental role in shaping the cell therapy development and manufacturing methods and technologies. Our technically strong team has been recognized by our partners for their ability to manufacture and release products successfully. Cellipont is committed in helping our partners to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. Cellipont Bioservices has a team of subject-matter-experts with extensive experience in the translation of your process from benchtop to bedside. Our team has hands on experience within autologous and allogenic cell therapies, and native & genetically modified cells. We have proven in-house scientific and manufacturing expertise for all phases of clinical products for our range of clients from Pre-Clinical to Late Phase commercialization. Our extensive experience spans across multiple product areas, including: CAR-T/TCR-T DCs Fibroblasts NK MSCs HSCs TIL Cell Banking (MCB, WCB) Feeder Cell Banks Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 1,800 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont Bioservices’ growth with deep knowledge of what it takes to succeed in this space. Cellipont cell therapy scientists in lab Located in The Woodlands, Texas right outside of Houston, Cellipont Bioservices facilities and quality systems are GMP-compliant. Cellipont Bioservices is privately held. Our core investor, Great Point Partners, is a dedicated healthcare-focused investment firm with an extensive track record in successfully building biologics services businesses. | Cellipont Bioservices firmly believes that cell therapies deserve personalized and dedicated support. Our team is comprised of tenured experts within the cell therapy space, working on advancing a wide spectrum of cell modalities from CAR-T, iPSC to DCs and MSCs. Located in The Woodlands, Texas, we are strategically located near some of the best medical centers in the world. We strive to lead alongside our partners from the forefront of innovation, translating cutting-edge processes from lab to bedside. | Cellipont Bioservices is a contract development and manufacturing organization (CDMO) dedicated exclusively to advanced therapies, supporting biotech and biopharma companies developing cell therapies from preclinical stages through commercial supply. The company provides integrated development, analytical, and GMP manufacturing solutions designed to accelerate clinical timelines while maintaining regulatory readiness and product quality. The organization has commercial manufacturing experience, and its facility is designed to support both early clinical development and commercial programs. The organization specializes in autologous and allogeneic cell therapy modalities, including CAR-T, TCR-T, NK, stem cell, and other engineered immune cell products. Its services are structured to bridge the gap between early process concepts and scalable, regulatory-compliant manufacturing workflows, enabling sponsors to transition efficiently from research into clinical production and long-term commercial supply.
CELLISTIC
Cellistic® specializes in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology using their Pulse® ™ and Echo®™ Platform. Its focus and expertise in iPSC reprogramming, gene editing using its proprietary STAR-CRISPRTM technology and differentiation development, positions the company to be the partner of choice for innovative cell therapy developers to advance into clinic. Leveraging more than a decade of scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cell therapies.
CdmoGen
A one-stop CTDMO, CdmoGen Co., Ltd. offers comprehensive and integrated contract services spanning the full length of the cell and gene therapy development process. From early optimization to the GMP and non-GMP manufacture of virus vector- and mRNA-based therapeutics, through CMC support and a robust panel of quality analyses, including lot release testing, CdmoGen is a full-service partner providing reliable and efficient developmental support. Recognized as the first GMP-compliant manufacturer approved by the Ministry of Food and Drug Safety (Republic of Korea), CdmoGen is also ISO17025-accredited, and has successfully completed over 250 GMP manufacturing and QC testing projects involving virus vector-based gene therapeutics and vaccines since 2016. In addition to continually working to increase its custom service capabilities, including validation studies and process, assay, and SOP development, CdmoGen brought online in 2023 a custom-built facility dedicated to the manufacture and testing of mRNA vaccines to further expand its service offerings. Virus seed stock and cell banking will also take place in this facility. Since its inception, CdmoGen has, through its experiences, expanded its knowledge base while establishing a track record for success, with a CTDMO customer having recently been approved for a clinical trial by the FDA. Moving forward, CdmoGen will do all it can to provide every partner with the support they need to achieve their own successes in the development of biopharmaceuticals and cell and gene therapeutics. | CdmoGen Co., Ltd. is a gene therapy new drug development company specializing in therapeutics for ocular diseases that also offers one-stop, full-service CTDMO services for virus vector- and mRNA technology-based biopharmaceuticals.
Cayman Chemical Company
Cayman Chemical has been providing high-quality research tools to the life sciences community for more than 45 years. Cayman offers an extensive catalog of biochemicals, analytical standards, lipids, proteins, antibodies, and assay kits to facilitate research in a broad range of areas relevant to cancer biology, such as cell signaling and regulation, epigenetics, cellular metabolism and mitochondrial function, oxidative stress, immuno-oncology, lipid nanoparticle (LNP) R&D, and more. Cayman also offers bioanalysis, assay development, immunopeptidome profiling, medicinal chemistry, structural biology, analytical chemistry, lipidomics, LNP development, custom chemical synthesis, and CGMP API manufacturing services to help make your research possible. | Cayman provides US-based integrated preclinical discovery and development services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 150 highly skilled scientists with expertise in medicinal and computational chemistry, structural biology, complex multi-step organic synthesis, GMP manufacturing, analytical chemistry, biomarker development, immunology, metabolism, cell biology, sample analysis, screening, and custom assay development. We offer a personalized, flexible approach that enables our clients to accelerate their drug discovery and development through a single-source partner, from novel drug design and synthesis to target identification and validation. | Cayman is a US-based CRO and CDMO providing chemistry and biology services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 170 highly skilled scientists with expertise in medicinal and computational chemistry, structural biology, complex multi-step organic synthesis, GMP API manufacturing, analytical chemistry, bioanalysis, LNP formulation and characterization, immunology, cellular metabolism, cell biology, sample analysis, screening, custom assay development, and more. We offer a personalized, flexible approach that enables our clients to address research questions from pre-clinical research to drug discovery and development through a single-source partner. | Cayman is a US-based CRO and CDMO providing chemistry and biology services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of more than 170 highly skilled scientists with expertise in medicinal chemistry, structural biology, bioanalysis, custom assay development, complex multi-step organic synthesis, analytical chemistry, GMP API manufacturing, and more. We offer a personalized, flexible approach that enables our clients to address research questions from basic research to drug discovery and development.
CatSci
Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, pre-formulation, analytical development, HPAPI development and non-GMP material supply, and recently launched their oligonucleotides capability. Through their partnership with AGC Pharma Chemicals, they offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. CatSci’s overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a ‘digital first, intelligent automation next’ business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers’ problems. Their purpose is and always will be to get medicines into the hands of patients in need. | CatSci Ltd is a UK-based award-winning innovation partner, dedicated to breaking down the silos in the development of small molecules, TACs and glues, and oligonucleotides to accelerate the delivery of life-changing medicines to patients in need. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule GMP API material supply, from grams to tonnes, with seamless knowledge transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). | CatSci Ltd is an award-winning innovation partner, dedicated to breaking down the silos in the CMC development of small molecules, TACS, glues, oligonucleotides and other complex medicines to accelerate the delivery of life-changing therapeutics to patients. We proudly serve customers across the globe with projects, meeting their needs from candidate selection to product launch and beyond. Our tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, we provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. We possess a range of critical enabling technologies in research, development and manufacturing of small molecule and new modality therapeutics, with specialist facilities in chemical development, catalysis, material science, pre-formulation, HPAPI development, GMP analytical services, and oligonucleotide R&D and supply. Through our partnership with AGC Pharma Chemicals, we offer scalable small molecule API manufacturing, from grams to tonnes, with complete accountability of tech transfer. Agile, commercially minded and scientifically led, CatSci leverages its highly qualified technical team and state-of-the-art facilities to empower our customers to create affordable, best-in-class therapeutics in a safer, greener and more cost-effective way. Together, we can meet the evolving healthcare needs of the world. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees), and the 2022 Cardiff Business Award (International Business of the Year). | Spun out of AstraZeneca in 2010, CatSci is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines. They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility. CatSci’s tailored services include route scouting and selection, initial scale-up and risk management for early development. For later development, they provide process design, assessment and optimisation, scale-up for clinical and commercial manufacture, tech transfer and post-approval improvements. They have specialist facilities in Process R&D, catalysis, high pressure reactions, crystallisation, preformulation, analytical development, HPAPI development and oligonucleotide development, they recently launched their peptide and bioscience capability.
Catalent
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. | Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. | Catalent is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
BSP PHARMACEUTICALS S.p.A
BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a specific focus on innovative compounds. With full containment facility, applying the most advanced and safe technologies, BSP can offer capabilities with a wide range of batch sizes providing flexibility to sustain preclinical, clinical and commercial manufacturing. The facility is designed to handle small molecules and large molecules, including ADCs (from Conjugation to Fill Finish), mAbs (including bi-specific), synthetic peptides, oligonucleotides, lipidic nanomedicine Production area includes: – a plant dedicated to Cytotoxic compounds, small and large molecules, (OEL
Bora Biologics and Bora Pharmaceuticals
BORA BIOLOGICS AND BORA PHARMACEUTICALS UNLOCKING THE FUTURE OF BIOLOGICS TOGETHER Join us at Booth #2087 to discover how Bora Biologics can accelerate your projects from concept to commercialization with unmatched speed and precision. As a leading Contract Development and Manufacturing Organization (CDMO), we offer seamless end-to-end solutions for biologics, combining our innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing and final packaging of clinical and commercial products. Collaborating with us means leveraging a proven track record of excellence, ensuring exceptional quality, seamless communication, and a collaborative spirit that propels your success. PROVEN TRACK RECORD With over 45 biologics and biosimilars developed, 100 successful cGMP batches delivered, and 2 commercially approved biosimilars in the U.S. and Canada, Bora Biologics is a trusted partner in the biologics industry. Our partnerships with Bora Pharmaceuticals and biotech companies around the world underscores our reliability and expertise in navigating complex projects. DRUG SUBSTANCE MANUFACTURING EXCELLENCE & INTEGRATED FILL/FINISH OFFERING Bora Biologics combines decades of expertise with state-of-the-art facilities and a commitment to innovation, positioning us as an industry leader in biologics manufacturing. Our FDA-registered facility in San Diego, California, is equipped for commercial-scale GMP manufacturing, featuring modular cleanrooms and advanced single-use bioreactor trains that support large-scale production scaling up to 2000L batches. Our Taipei, Taiwan facility is known for its cutting-edge cGMP clinical manufacturing capabilities, leveraging single-use technology and scalable platform technology to support global clinical trials. Our combined manufacturing footprint spans over 130,000sf of GMP manufacturing space. Leveraging Bora Pharmaceuticals’ 87,000sf cGMP drug product manufacturing facility in Baltimore, Maryland, US, we offer clients a streamlined and integrated fill/finish solution for vials and pre-filled syringes in liquid and lyophilized formulations. This facility provides clinical and commercial fill/finish manufacturing through its state-of-the-art Groninger FlexPro 50 filling line, ideal for high-value biological products, and provides on-site inspection, labeling and packaging and comprehensive analytical and testing services. With extensive experience in tech transfer, scale up, and commercialization, Bora Pharmaceuticals is well equipped to support your unique fill/finish program needs. COMPREHENSIVE DEVELOPMENT SERVICES At Bora Biologics, we understand that the path from IND to BLA to commercialization is complex. Our development services are designed to streamline every stage of your biologics project, ensuring high-quality outcomes and timely delivery. We are your trusted partner, offering a wide range of development services, including contract development, tech transfer, cell line development, mammalian process development, microbial process development, analytical development, formulation development, and drug product development. NEXT-GEN TECHNOLOGY We utilize the latest equipment and upgraded technologies, ensuring efficient and scalable manufacturing and development processes. Our single-use systems and fully integrated platforms enhance flexibility and significantly reduce turnaround times, allowing us to quickly adapt to changing project requirements while maintaining the highest quality standards. EXPERTISE IN VARIOUS MODALITIES As a CDMO, we specialize in a wide range of biologics, including fusion proteins, antibodies, antibody derivatives, bi- and tri-specifics, ADCs, enzymes, and more. Our experienced team is dedicated to delivering high-quality products that meet stringent regulatory standards. HIGHLY QUALIFIED TEAM OF EXPERTS Our diverse team of scientists, engineers, and regulatory experts exudes deep knowledge, specialized skills, and experience, ensuring you benefit from best practices in biologics development, manufacturing, and commercialization. Over 50% of our employees hold advanced degrees, including PhDs and master’s degrees. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks. CLIENT-CENTRIC APPROACH We pride ourselves on a client-centric approach that fosters collaboration and transparency. By aligning our services with your specific goals, we accelerate timelines and enhance the potential for successful market entry. CONNECT WITH US We invite you to visit us at Booth #2087 to explore how the synergy between Bora Biologics and Bora Pharmaceuticals can elevate your biologics projects. Engage with our experts, discover our success stories, and learn how we can help you shape the future of pharmaceuticals. Our commitment to quality and innovation positions us as your preferred partner in navigating the complexities of biologics development. US Corporate Headquarters Bora Biologics 10394 Pacific Center Court San Diego, CA 92121 +1 858-210-4100 bd@borabiologics-us.com Taiwan Bora Biologics 3F, No 22, Sec 2, Shengyi Rd Zhubei City, Hsinchu County 302, Taiwan
Boehringer Ingelheim Biopharmaceuticals GmbH
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Boehringer Ingelheim BioXcellence™ creates solutions with its partners to reliably supply innovative therapies. One of the world’s largest manufacturers of biopharmaceuticals and an industry pioneer with in-depth experience, Boehringer Ingelheim BioXcellence™ so far has supplied more than 40 commercial products through its global network. | Boehringer Ingelheim is a leading research-driven biopharmaceutical company and creates value through innovation in areas of high unmet medical need. As one of the world’s largest manufacturers for biopharmaceuticals with in-depth experience in this field, the company is an industry pioneer and collaborates with top 20 pharma companies and innovative biotechs. Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come. We create solutions with our partners, building on our can-do attitude to improve patient health. Our business is empowered by more than 5,000 dedicated and well-trained employees in development, quality and manufacturing and has access to a global manufacturing network providing the entire production chain from DNA to Aseptic Filling. Our track records, both in commercial and clinical supply speak for themselves – since we started offering contract manufacturing in 1995, we have successfully brought 45 biologics to the market and have transferred and optimized more than 150 development and manufacturing projects at all stages from our customers to our facilities, as well as within our network. While collaborating with our partners we never lose sight of the patients that depend on biopharmaceutical therapies. We offer capabilities to complement your expertise, so together we can deliver better therapies. | As one of the world’s largest manufacturers of biopharmaceuticals, we leverage our in-depth industry experience for collaborating with top pharma and biotech companies. Our contract manufacturing business Boehringer Ingelheim BioXcellence™ is built on profound experience in key technologies – mammalian and microbial derived biopharmaceuticals – and supported by a global manufacturing network ranging from US via Europe to Asia that handles the entire production chain, from DNA to aseptic filling. Our track record in commercial and clinical supply is impressive – since initiating contract manufacturing in 1998, we’ve successfully brought 48 biologics to market. Furthermore, we transferred and optimized over 150 development and manufacturing projects focusing on late stage and commercial supply. We collaborate with partners worldwide, offering capabilities that complement their expertise. Together we turn biologic innovation into commercial success. Boehringer Ingelheim BioXcellence™ is always open to partner on contract manufacturing needs concerning your business. Contact us via www.BioXcellence.com | BioXcellence Manufacturing – Tailored Capacities. Reliable Supply. Your Success, Our Commitment. Boehringer Ingelheim BioXcellence™ is one of the leading biopharmaceutical contract manufacturers — a reliable partner that accompanies customers throughout the life cycle of their products. We provide E2E biopharmaceutical manufacturing based on mammalian cell culture and microbial fermentation, streamlining your product’s lifecycle. We have extensive experience with a variety of different host cells, producing a broad range of molecules in accordance with cGMP manufacturing guidelines and covering all stages of development, including aseptic filling. Our focus is on creating value for our customers through robust processes, optimal preparation for launch, and global clinical and commercial supplies of high-quality biopharmaceuticals. With over 40 years of biotechnology experience and a team of dedicated and highly trained employees, we have helped our customers bring more than 45 biopharmaceutical medicines to the market. Our network of manufacturing facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria, and Shanghai in China. With around 460 kL for mammalian cell culture and 12 kL for microbial fermentation in fully licensed multiproduct facilities we are your right partner for high-quality global supplies of biopharmaceuticals to patients. Let’s build a future together based on our history. We have capabilities to complement your expertise and are committed to turning your biologic innovation into commercial reality.
BIOVECTRA
BIOVECTRA (www.biovectra.com) is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, lipids, pDNA, mRNA and LNP manufacturing, and fill/finish for drug products. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, over 630 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada, we assure our programs advance on time and with the highest quality outcomes. | BIOVECTRA is a North American CDMO with over 50 years of experience specializing in clinical-to-commercial scale production of high-quality regulated active pharmaceutical ingredients (APIs) and intermediates. [[ Our Expertise ]] – Biologics – Large molecule therapeutics and bioprocessing solutions – Synthetic Small Molecules – Small-molecule API and intermediate manufacturing – Plasmid DNA (pDNA) & Messenger RNA (mRNA) – Nucleic acid development and production – Lipid Nanoparticle (LNP) Formulations – Drug delivery solutions for nucleic acid therapies – Highly Potent APIs (HPAPIs) – Safe and scalable production of complex compounds – Bioreagents – Custom enzyme and reagent manufacturing for diagnostics and research [[ Comprehensive Services ]] – Process Development & Scale-up – From early-stage research to commercial manufacturing – Analytical Development & Quality Control – Ensuring product integrity and compliance – Technology Transfer & cGMP Manufacturing – Seamless transition from lab to production – Clinical & Commercial Manufacturing – Supporting drug programs at all stages [[ Why BIOVECTRA? ]] – Trusted CDMO Partner – Decades of expertise in solving complex therapeutic challenges and a 2025 CDMO Leadership award winner in the Biologics category – State-of-the-Art Facilities – cGMP-compliant manufacturing sites in Prince Edward Island and Nova Scotia, Canada – Strong Team & Industry Commitment – Over 600 employees dedicated to innovation and quality In fall 2024, BIOVECTRA was acquired by Agilent Technologies, further strengthening our ability to support next-generation treatments and deliver greater value to our clients. Our mission remains the same: to develop and manufacture high-quality products that improve patients’ lives.